(Q48032304)

7 February 2018

title

Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells (English)

1 reference

7 February 2018

1 reference

Shuhong Han

1

1 reference

7 February 2018

Bei Wang

2

1 reference

7 February 2018

Matthew J Cotter

3

1 reference

7 February 2018

Li-Jun Yang

4

1 reference

7 February 2018

James Zucali

5

1 reference

7 February 2018

Jan S Moreb

6

1 reference

7 February 2018

Lung-Ji Chang

7

1 reference

7 February 2018

publication date

11 December 2007

1 reference

7 February 2018

published in

Molecular Therapy

1 reference

7 February 2018

volume

16

1 reference

7 February 2018

issue

2

1 reference

7 February 2018

page(s)

269-279

1 reference

7 February 2018

Novel therapeutic approaches for multiple myeloma

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

State of the art therapy in multiple myeloma and future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Allogeneic stem cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

The changing landscape of myeloma therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Active immunotherapy of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Mechanisms and functional significance of tumour-induced dendritic-cell defects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Heat shock protein-peptide complexes in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Regulatory T cells in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Dysfunctional T regulatory cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Altered immunity accompanies disease progression in a mouse model of prostate dysplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

The anatomy of T-cell activation and tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Emerging possibilities in the development and function of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Cross-presentation of phage particle antigen in MHC class II and endoplasmic reticulum marker-positive compartments.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300369

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300369

1 reference

7 February 2018

release_ablilw6sj5d5niu5ze2ll37upq

Fatcat ID

0 references

1 reference

7 February 2018